LENZ Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 11, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 11, 2026

LENZ$4.10-4.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)

	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
Revenue:
Product sales, net	$1,736	$—	$3,387	$—
License revenue	3,750	5,000	4,000	5,000
Total revenue	5,486	5,000	7,387	5,000
Operating expenses:
Cost of sales	280	—	1,356	—
Selling, general and administrative	39,378	12,796	84,338	23,909
Research and development	—	9,061	—	14,879
Total operating expenses	39,658	21,857	85,694	38,788
Loss from operations	(34,172)	(16,857)	(78,307)	(33,788)
Other (expense) income:
Other (expense) income	(13)	199	(10)	188
Interest income	2,270	2,246	4,914	4,569
Total other income, net	2,257	2,445	4,904	4,757
Net loss before income taxes	(31,915)	(14,412)	(73,403)	(29,031)
Income tax expense	3	500	3	500
Net loss	$(31,918)	$(14,912)	$(73,406)	$(29,531)
Other comprehensive loss:
Unrealized loss on marketable securities	(179)	(85)	(871)	(158)
Comprehensive loss	$(32,097)	$(14,997)	$(74,277)	$(29,689)
Net loss per share, basic and diluted	$(1.02)	$(0.53)	$(2.34)	$(1.06)
Weighted-average common shares outstanding, basic and diluted	31,374,311	28,079,071	31,363,566	27,804,112

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.